enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with...

Related Keywords

Canada ,Boston ,Massachusetts ,United States ,Montreal ,Quebec ,Canadian ,Alex Nichols ,Richard Bryce ,Ryan Daws ,Lota Zoth ,Derivatized Oligochitosan ,Jason Hanson ,Public Company ,Nasdaq ,Forbion European Acquisition Corporation ,Clinical Program Progress ,Company Board Of Directors ,Exchange Commission ,Forbion European Acquisition Corp ,Company Audit Committee Chair ,Gene Holdings Inc ,Company Annual Report On Form ,Gene Holdings ,Chief Executive Officer ,Chief Financial Officer ,Hercules Capital ,Business Highlights ,Company Launch ,Program Progress ,Secondary Endpoints ,Hercules Capital Debt Facility ,Leadership Hires ,Chief Operating Officer ,Chief Medical Officer ,Chief Financial ,Audit Committee ,Upcoming Anticipated ,Annual Meeting ,Urologic Oncology ,Reverse Recapitalization ,Bacillus Calmette Gu ,Dually Derivatized Oligochitosan ,Private Securities Litigation Reform Act ,Annual Report ,Consolidated Statements ,Ended October ,